836-59-9

Usage

Uses

4-[2-(4-Bromophenoxy)ethyl]morpholine is a useful intermediate for organic synthesis.

InChI:InChI=1/C12H16BrNO2/c13-11-1-3-12(4-2-11)16-10-7-14-5-8-15-9-6-14/h1-4H,5-10H2

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 106-41-2 4-bromo-phenol 
• 110-91-8 morpholine 
• 55162-34-0 1-bromo-4-(2-chloroethoxy)benzene 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 

Downstream Products

• 988-43-2 4-{2-[4-(5-methoxy-2-phenyl-3H-inden-1-yl)-phenoxy]-ethyl}-morpholine 
• 194935-47-2 1-[4-(2-morpholinoethoxy)phenyl]-2-phenyl-1-selenophen-2-ylbutan-1-ol 
• 690636-28-3 4-(2-( 4-( 4, 4, 5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)morpholine 
• 1038395-62-8 4-(2-(4-(6-fluoropyridin-3-yl)phenoxy)ethyl)morpholine 
• 1467060-34-9 4-{2-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenoxy]ethyl}morpholine 
• 1467060-35-0 6-chloro-5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}-1H-indole-3-carbaldehyde 
• 1467057-63-1 6-chloro-5-{4-[2-(morpholin-4-yl)ethoxy]phenyl}-1H-indole-3-carboxylic acid 
• 1038395-65-1 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide dihydrochloride 
• 1080645-95-9 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide mesylate 
• 897016-82-9 KX2-391 
• 1038395-63-9 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetonitrile 
• 1038395-64-0 methyl 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetate 
• 151825-62-6 2-(4-chlorophenylmethylene)-3-(2-morpholinoethoxy)phenyl-6-methoxy-2,3-dihydrobenzofuran-3-ol 

Relevant academic research and scientific papers

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

The present disclosure provides BET inhibitors of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of treating a patient comprising administering a bromo- and extra-terminal (BET) domain inhibitor for the treatment of FSHD which modulates DUX4 expression. In some embodiments, the present methods comprise using one or more BET inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK

The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF

The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2- mopholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE

The invention relates to compositions of N-benzyl-2-(5-(4-(2- morpholinoethoxy)phenyl)pyridin-2-yl)acetamide (KX2-391) and methods for modulating one or more components of a kinase cascade.

Antiinflammation agents

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism, infection and cell proliferation. The subject compounds contain a fused heterobicyclic ring.

Anilide derivative, production and use thereof

This invention is to provide a compound of the formula: wherein R1is an optionally substituted 5- to 6-membered ring; the ring A is an optionally substituted 6- to 7-membered ring; the ring B is an optionally substituted benzene ring; n is an integer of 1 or 2; Z is a chemical bond or a divalent group; R2is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, (2) an optionally substituted nitrogen-containing heterocyclic ring group which may contain a sulfur atom or an oxygen atom as ring constituting atoms and wherein a nitrogen atom may form a quaternary ammonium, (3) a group binding through a sulfur atom or (4) a group of the formula: ?wherein k is 0 or 1, and when k is 0, a phosphorus atom may form a phosphonium; and R5and R6are independently an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted amino group, and R5and R6may bind to each other to form a cyclic group together with the adjacent phosphorus atom, or a salt thereof , which is useful for antagonizing CCR5 and also for the prevention and treatment of infectious disease of HIV.